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INTRODUCTION: Chronic kidney disease (CKD) is a worldwide public health
problem, related to increased morbidity and mortality. Glomerulopathies represent
major causes of CKD and require complicated diagnostics. Standard of care includes
kidney biopsy in order to confirm the type of nephropathy. However, biopsy brings
specific risks. Therefore, non-invasive diagnostic and prognostic methods are sought.
Urinary proteomics emerged as safe and promising tool, but still requires development
and improvements. Our previous studies which are part of European Patent Application
from 10th June 2016 (WO/2017/212463), identified urinary markers of IgA nephropathy.
They included among others: alpha-1B-glycoprotein (A1BG), alpha-l-acid glycoprotein 1
(ORM-1), ferritin light chain (FTL) and serotransferrin (TF). The aim of this study was to
evaluate them in comparison to patients with glomerulopathies of different etiologies,
such as lupus nephritis (LN) and membranous nephropathy (MN).
METHODS: This proteomic study included patients with CKD (41 IgAN, 33 LN, 26
MN, 6 with erytrocyturia of unknown etiology) and 19 healthy controls. Urine samples
were obtained from a midstream of the: first-morning (FM) and second- or third-
morning (SPOT) sample. The SPOT samples were processed up to 2 h and FM samples
up to 4 h after collection, by agitating and gently inverting 4-6 times, portioned into 2-
ml aliquots and stored at -80C for further measurements. Western Blotting was used
for analysis of the SPOT and FM samples, ELISA and mass spectrometry for SPOT
urine only. The results were related to demographic data, standard laboratory tests and
GFR estimated with use of Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation.
RESULTS: The urinary concentrations of A1BG, ORM-1, FTL and TF were found to be
higher in CKD patients than in healthy controls. Moreover, these proteins varied
depending on the disease. According to ELISA measurements, patients with IgAN,
erytrocyturia and LN had significantly more A1BG and ORM-1 (p < 0.05), whereas TF
was more elevated in LN and MN individuals comparing to healthy controls. The
western blot analysis revealed significantly elevated level of A1BG, ORM-1 and FTL in
IgAN, LN and MN, comparing to healthy control. Additionally, it revealed
fragmentation of A1BG in several patients and the bottom range bands tended to be
most prominently elevated in IgAN patients. Mass spectrometry confirmed differences
between the diseases according to the specific amino acids fragments of each tested
protein. Figure 1. Western blot scans for urinary A1BG, ORM-1 and FTL in CKD
patients (2-4) and healthy controls (1).
CONCLUSIONS: The urinary concentrations of A1BG, ORM-1, FTL and TF are
elevated in CKD patients and vary depending on the type of nephropathy. This
observation suggests their differential roles in the pathophysiology of the given
diseases, and we believe their evaluation may help distinguishing between
nephropathies. Further studies are desired to establish the role of these urinary proteins
in non-invasive disease differentiation.
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